The immunotherapeutic contribution to allogeneic stem cell transplantation's (SCT's) curative potential in hematological diseases is well recognized, with alloreactive donor T and NK lymphocytes mediating a graft-versus-tumor (GVT) effect. 1 Recent advances in our understanding of immune regulatory pathways have identified immune check-point exploitation by cancer cells in the tumor microenvironment as a 'druggable' mechanism of immune evasion. The programmed death-1 (PD-1) regulatory pathway is active in several tumors and a potent immunotherapeutic target, with PD-1 inhibitors eliciting antitumor responses. [2] [3] [4] Nivolumab, an anti-PD-1 monoclonal antibody (Ab), is approved therapy for melanoma 5 and non-small squamous cell lung cancer; 6 it also exhibits robust clinical activity in refractory/relapsed Hodgkin lymphoma (HL). 7 Although PD-1 inhibition may effectively unleash GVT responses in relapsed HL after allogeneic SCT, the risks of graft-versus-host disease (GvHD) or graft rejection are unknown. We report herein the effective and safe use of nivolumab in a patient with relapsed/refractory HL progression after allogeneic SCT.
A 52-year-old female with classical HL involving lymph nodes, bones and breast, refractory to ABVD, brentuximab vedotin (BV), combination chemotherapy and investigational lenalidomide/ temsirolimus (NCT01076543) underwent allogeneic SCT 16 months after diagnosis. She received myeloablative cyclophosphamide and total body irradiation (TBI) and a peripheral blood allograft from her HLA-matched sister in October 2014, with tacrolimus and low-dose methotrexate for alloprophylaxis. Clinical and radiographic disease progression was evident by day 100 and continued in spite of withdrawal of immunosuppression; there was no evidence of GvHD. A lymph node biopsy confirmed relapse, whereas immunohistochemistry showed strong pro- briefly received oxygen supplementation (3 L/min by nasal cannula); microbial tests were negative. Pneumonitis and hepatitis responded promptly to oral prednisone, 2 mg/kg per day for 1 week and tapered over 5 weeks to 10 mg/day. Significant clinical response was noted within 3 weeks of nivolumab, with significant reductions in her breast mass and axillary nodes, reduced sternal bone pain and decrease in the serum LDH from 1027 to 722 units/L (ULN: 618). Upon complete resolution of pneumonitis and hepatitis (7 weeks after the initial dose), she received a second dose of nivolumab, further reduced to 0.5 mg/kg, whereas continuing on prednisone 10 mg daily. There was no recurrence of hepatitis nor pneumonitis. PET/CT 2 weeks after the second dose of nivolumab demonstrated marked decrease in the size and metabolic activity of all lesions (Figures 2c-e) . At last follow-up, 5 months after initial treatment, she had received four additional injections of nivolumab at escalating doses of 1, 2 and 3 mg/kg and continued to do well without progression nor recurrent side effects; a subsequent PET/CT scan after the sixth injection showed further improvement in the size and metabolic activity of the residual left axillary adenopathy with no new abnormality. At this time, she has no signs of GvHD, the bone marrow allograft function remains robust, and serial chimerism assessments demonstrate continued full-donor engraftment. Biweekly maintenance nivolumab therapy is ongoing. In addition, based on the success of our first experience, we treated a second patient with relapsed and refractory HL after haploidentical allogeneic SCT using nivolumab at a dose level of 1 mg/kg. Although follow-up is very short for this second patient (2.5 months), after four treatments, repeat imaging studies showed a partial nodal response including~50% reduction in SUV values with no immunologic complications, cytopenias nor GvHD.
Our patient exhibited a limited GVT effect after allogeneic SCT, with disease progression and no evidence of GvHD. Following treatment with nivolumab, a major clinical response was observed in her highly refractory HL. It is reassuring that her response, presumably immune mediated by donor tumor-infiltrating lymphocytes, could be achieved without GvHD or graft rejection. In HL, constitutive PD-L1/PD-L2 expression in HRS cells 8 may render them exquisitely sensitive to disruption of the PD-1 pathway, accounting for a tumor-specific immune response. Although PD-1 has been implicated in regulating alloreactivity, our patient appears to have maintained allogeneic tolerance. Grade 2 pneumonitis and hepatitis responded to corticosteroid therapy, and subsequent administration with dose escalation has been well tolerated thus far. The durability of this response remains to be seen and thus the optimal duration of therapy is unclear. Nonetheless, this first reported case suggests that immunotherapy targeting PD-1 may be safe and effective in patients with HL progression after allogeneic SCT and warrants prospective study.
